TROY Modulates Cancer Stem-Like Cell Properties and Gefitinib Resistance Through EMT Signaling in Non–Small Cell Lung Cancer

Targeted therapy has made breakthrough progress in the treatment of advanced non–small cell lung cancer (NSCLC) in the last 20 years. Despite that, acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is an urgent clinical problem. Our study established an acq...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Linying, Yu, Yuman, Xu, Liming, Wang, Xiaoling, Zhou, Jianying, Wang, Yuehong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136171/
https://www.ncbi.nlm.nih.gov/pubmed/35646083
http://dx.doi.org/10.3389/fgene.2022.881875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136171/
https://www.ncbi.nlm.nih.gov/pubmed/35646083
http://dx.doi.org/10.3389/fgene.2022.881875

Ejemplares similares